Course
Queensland primary lecture program, series 1
8am-2pm
ANZCA QLD regional office Brisbane

This interactive long course consists of a series of lectures covering core topics of the primary examination.
Course dates
The course is held on five Saturdays over a five month period:
- 22 February, 2025
- 15 March, 2025
- 12 April, 2025
- 10 May, 2025
- 14 June, 2025
Cost and registration
This course is open to trainees from all Australian regions and New Zealand.
Please email to register your interest.
Registration type | Location | Fee (per series) | Eligibility |
In-person | ANZCA Queensland regional office | $A440 | Gold Coast Hospital and Health Service Ipswich Hospital Logan Hospital Mater Hospital and Health Service Princess Alexandra Hospital Queen Elizabeth II Jubilee Hospital Redcliffe Hospital Redland Hospital Royal Brisbane and Women's Hospital Sunshine Coast Hospital and Health Service The Prince Charles Hospital |
Virtual | Zoom | $A440 | Queensland trainees based outside of the above metropolitan areas. Other Australian regions and New Zealand. |
You might also be interested in...

ANZCA SA Office
SA/NT part one long course
This face-to-face weekly course is for SA/NT trainees preparing for the ANZCA primary exam.

Participating hospitals
SA/NT part two long course
This weekly course is for SA/NT trainees preparing for the ANZCA final exam.

ANZCA WA Office
2025 WA ACE Lecture Series
A Successful Trial and Exciting Developments for 2025.